2002
Reticulated platelets predict platelet count recovery following chemotherapy
Wang C, Smith BR, Ault KA, Rinder HM. Reticulated platelets predict platelet count recovery following chemotherapy. Transfusion 2002, 42: 368-374. PMID: 11961244, DOI: 10.1046/j.1537-2995.2002.00040.x.Peer-Reviewed Original ResearchConceptsPlatelet count recoveryPercentage of RPProphylactic platelet transfusionsCount recoveryPlatelet transfusionsPlatelet recoveryStress thrombopoiesisPlatelet count increaseIdiopathic thrombocytopenic purpuraPlatelet count nadirsChemotherapy-induced thrombocytopeniaNegative predictive valueEvaluable patientsMarrow suppressionThrombocytopenic purpuraChemotherapy patientsThrombocytopenia patientsLower percentagePatientsPredictive valueReproducible indexThrombocytopeniaTransfusionChemotherapyIncreased percentage
1991
Selective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies
Antin J, Bierer B, Smith B, Ferrara J, Guinan E, Sieff C, Golan D, Macklis R, Tarbell N, Lynch E, Reichert T, Blythman H, Bouloux C, Rappeport J, Burakoff S, Weinstein H. Selective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies. Blood 1991, 78: 2139-2149. PMID: 1717080, DOI: 10.1182/blood.v78.8.2139.2139.Peer-Reviewed Original ResearchConceptsAnti-CD5 MoAbHigh-risk patientsGraft failureHost diseaseHematologic malignanciesT cellsEpstein-Barr virus-associated lymphoproliferative disorderBone marrowActuarial event-free survivalBone marrow T lymphocytesAnti-CD5 monoclonal antibodyDiagnosis of myelodysplasiaMarrow T lymphocytesEvent-free survivalLow-risk patientsLate graft failureTotal body irradiationSignificant risk factorsRisk of relapseMajor histocompatibility complexActuarial survivalAcute graftAcute GVHDChronic GVHDEvaluable patientsSelective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies
Antin J, Bierer B, Smith B, Ferrara J, Guinan E, Sieff C, Golan D, Macklis R, Tarbell N, Lynch E. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991, 78: 2139-2149. DOI: 10.1182/blood.v78.8.2139.bloodjournal7882139.Peer-Reviewed Original ResearchAnti-CD5 MoAbHigh-risk patientsGraft failureHost diseaseHematologic malignanciesT cellsEpstein-Barr virus-associated lymphoproliferative disorderBone marrowActuarial event-free survivalBone marrow T lymphocytesAnti-CD5 monoclonal antibodyDiagnosis of myelodysplasiaMarrow T lymphocytesEvent-free survivalLow-risk patientsLate graft failureTotal body irradiationSignificant risk factorsRisk of relapseMajor histocompatibility complexActuarial survivalAcute graftAcute GVHDChronic GVHDEvaluable patients